Last reviewed · How we verify
Tj-14 — Competitive Intelligence Brief
unknown
Cyclin-dependent kinase 1, Lysine-specific histone demethylase 1A, Prolyl endopeptidase
Other
Live · refreshed every 30 min
Target snapshot
Tj-14 (baicalin). Tj-14 works by blocking the enzyme LSD1, which is involved in turning off genes by removing methyl groups from histones.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tj-14 TARGET | baicalin | unknown | Cyclin-dependent kinase 1, Lysine-specific histone demethylase 1A, Prolyl endopeptidase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Tj-14 — Competitive Intelligence Brief. https://druglandscape.com/ci/baicalin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing